Navigating Recent Advances in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): Expert Perspectives on Immunotherapy in an Evolving Treatment Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the webinar held November 11, 2020

This activity is valid from February 1, 2021 to March 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the US, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with HPV has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in past years, the prognosis for metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients.

Upon completion of this activity, participants will be able to:

  • Examine recent clinical data on immunotherapies in the first-line treatment of metastatic head and neck squamous cell carcinoma (HNSCC)

  • Integrate immune checkpoint inhibitors into the management of patients with recurrent/metastatic HNSCC

  • Identify metastatic HNSCC patients who would potentially benefit from the use of checkpoint inhibitors

  • Analyze strategies to optimally sequence immunotherapy regimens in metastatic HNSCC

  • Explore strategies to mitigate immune-related adverse events in patients with HNSCC receiving immunotherapy or multimodal combinations with immunotherapy components

     

Faculty: Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego Health
Co-director, San Diego Center for Precision Immunotherapy
Co-director, Head and Neck Cancer Center of Excellence
UC San Diego Moores Cancer Center

Disclosure:

Dr. Cohen serves as a consultant for ALX Oncology, Ascendis, Bayer, Bioline Rx, BMS, Debio, Dynavax, MSD, Merck, Regeneron, and Sanofi. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue